AM-281

AM-281 is a compound that acts as a potent and selective antagonist for the CB1 receptor, and was developed for use in scientific research. It has been used in the study of the endocannabinoid system and its role in various physiological processes, and has been instrumental in the development of new therapeutic drugs.

Chemistry[edit | edit source]

AM-281 is a derivative of cannabinoid, a class of chemical compounds that interact with the cannabinoid receptors in the body. It is structurally similar to other cannabinoid antagonists such as SR141716A, but has a higher affinity for the CB1 receptor.

Pharmacology[edit | edit source]

AM-281 acts by binding to the CB1 receptor, blocking the action of endogenous cannabinoids such as anandamide and 2-AG. This makes it a valuable tool in the study of the endocannabinoid system, as it allows researchers to investigate the effects of blocking cannabinoid activity.

Therapeutic potential[edit | edit source]

Research has suggested that AM-281 may have potential therapeutic applications. For example, it has been shown to reduce food intake in animal models, suggesting it could be used in the treatment of obesity. It has also been shown to have anti-inflammatory effects, which could make it useful in the treatment of conditions such as arthritis or multiple sclerosis.

Safety and side effects[edit | edit source]

As with any drug, AM-281 has potential side effects. These can include nausea, vomiting, and changes in mood. However, these effects are generally mild and temporary. More research is needed to fully understand the safety profile of AM-281.